STOCK TITAN

Sensei Biotherapeutics, Inc. - SNSE STOCK NEWS

Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage immuno-oncology company, renowned for its innovation in next-generation cancer immunotherapies. Headquartered in Gaithersburg, MD, Sensei leverages its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform to develop cutting-edge therapeutics designed to harness the body's immune system against cancer. The company’s leading product candidates include SNS-101, SNS-102, SNS-103, and SNS-201, all of which are conditionally active antibodies targeting different immunosuppressive markers within the tumor microenvironment.

Sensei’s flagship candidate, SNS-101, is designed to block the VISTA (V-domain Ig suppressor of T cell activation) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 is currently undergoing a multi-center Phase 1/2 clinical trial, evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo® (cemiplimab), in patients with advanced solid tumors. Initial data are promising, showing SNS-101 to be well-tolerated and demonstrating clinical activity, particularly in tumor types typically resistant to PD-1 monotherapy.

Other promising candidates include SNS-102, targeting VSIG-4 (V-Set and Immunoglobulin Domain Containing 4), and SNS-103, targeting CD39 (ecto-nucleoside triphosphate diphosphohydrolase-1), as well as SNS-201, a conditionally active VISTAxCD28 bispecific antibody. The company has established key academic collaborations, including with Brown University, to bolster its research and development efforts.

Financially, Sensei maintains a strong balance sheet with cash reserves projected to fund operations into the second half of 2025. Recent financial updates show reduced R&D and G&A expenses due to strategic restructuring, leading to a narrower net loss. The company is focused on advancing its clinical trials, with expected milestones including initial combination safety and pharmacokinetic data for SNS-101 in early 2024, followed by topline monotherapy data later in the year.

For more information, visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Rhea-AI Summary

Sensei Biotherapeutics, a leader in immunotherapy, announced that CEO John Celebi will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:00 p.m. ET, both in-person and virtually in New York, NY. Investors can access a live webcast of the presentation on the company's website, with a replay available for 90 days afterward. Sensei focuses on developing innovative cancer therapies, utilizing its TMAb™ and ImmunoPhage™ platforms. Their lead therapeutic candidate, SNS-101, targets the VISTA checkpoint to enhance T cell activity in the tumor microenvironment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
conferences
-
Rhea-AI Summary

Sensei Biotherapeutics (SNSE) reported Q1 2022 financial results, highlighting a net loss of $12.4 million, up from $8.0 million in Q1 2021. The company's cash reserves stood at $136.2 million, sufficient to fund operations through Q1 2025. Progress on the TMAb™ platform includes promising preclinical data for SNS-101, an anti-VISTA antibody targeting solid tumors, which showed selective binding in low pH environments. The firm also anticipates submitting an IND for SNS-101 in the first half of 2023 following successful GMP manufacturing initiation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
-
Rhea-AI Summary

Sensei Biotherapeutics (NASDAQ: SNSE) announced significant advancements in its pipeline with the initiation of new therapeutic programs, including SNS-101, an anti-VISTA antibody. The company reported a strong cash position of $147.6 million as of December 31, 2021, providing a runway into the first half of 2024. Additionally, the management team was strengthened with key appointments. SNS-101 shows promise against the VISTA immune checkpoint, vital for overcoming challenges in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.62%
Tags
Rhea-AI Summary

Sensei Biotherapeutics (NASDAQ: SNSE) has appointed William Ringo as chair of its Board of Directors, enhancing leadership during a pivotal phase for the company. Ringo, with over 40 years in the pharmaceutical and biotech industries, brings extensive experience from Pfizer and Eli Lilly. His leadership is expected to support Sensei's objectives in developing innovative cancer therapies, particularly through its unique TMAb™ and ImmunoPhage™ platforms. The company is focused on advancing treatments such as SNS-101 and SNS-401-NG.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.62%
Tags
management
-
Rhea-AI Summary

Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Company leaders, including John Celebi and Erin Colgan, will present virtually on March 15 at 10:40 am ET. A replay of the presentation will be available for 90 days on their website. Sensei Biotherapeutics focuses on developing next-generation cancer immunotherapies, utilizing its innovative TMAb and ImmunoPhage platforms for personalized treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences
-
Rhea-AI Summary

BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in Citi's 2022 Immuno-Oncology Summit. Dr. Robert Pierce, Chief R&D Officer, will engage in a fireside chat on February 16, 2022, at 2:30 PM ET. The event will be webcast live, with a replay available for 90 days on the company's website. Sensei Biotherapeutics specializes in next-generation immunotherapies for cancer, utilizing its TMAb™ platform for antibody development and ImmunoPhage™ platform to create personalized treatments for various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
conferences
Rhea-AI Summary

Sensei Biotherapeutics has announced key promotions within its leadership team, appointing Erin Colgan as Chief Financial Officer and Robert Pierce, M.D. as Chief Research & Development Officer. Colgan, previously Senior VP of Finance, brings extensive experience from Intarcia Therapeutics and Vertex Pharmaceuticals. Dr. Pierce, who has over 20 years in scientific leadership, shifted from Chief Scientific Officer, enhancing his role to include drug discovery and clinical development. CEO John Celebi expressed confidence in their capabilities to drive the company’s future growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
-
Rhea-AI Summary

Sensei Biotherapeutics (NASDAQ: SNSE) announced its inclusion in the NASDAQ Biotechnology Index, effective December 20, 2021. This index encompasses biotechnology and pharmaceutical companies meeting specific eligibility criteria, including trading volume and market capitalization. This recognition highlights Sensei's position in the biotechnology sector as it pursues next-generation cancer therapeutics through its innovative TMAb™ and ImmunoPhage™ platforms. The company is advancing its product pipeline, including the antibody SNS-101 and ImmunoPhage cocktail SNS-401-NG for treating cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
Rhea-AI Summary

Sensei Biotherapeutics (NASDAQ: SNSE) announced participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. CEO John Celebi and SVP Erin Colgan will engage in a pre-recorded fireside chat, available for streaming starting November 22, 2021, at 10:00 AM ET on the company’s website. This event highlights Sensei’s innovative immunotherapy approaches, including its TMAb™ and ImmunoPhage™ platforms, focusing on cancer treatments like SNS-101 and the preclinical SNS-401-NG targeting Merkel Cell Carcinoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
conferences

FAQ

What is the current stock price of Sensei Biotherapeutics (SNSE)?

The current stock price of Sensei Biotherapeutics (SNSE) is $0.4499 as of December 20, 2024.

What is the market cap of Sensei Biotherapeutics (SNSE)?

The market cap of Sensei Biotherapeutics (SNSE) is approximately 11.1M.

What is Sensei Biotherapeutics, Inc.?

Sensei Biotherapeutics, Inc. is a clinical stage immuno-oncology company focused on the development of next-generation cancer immunotherapies.

What products is Sensei developing?

Sensei is developing several conditionally active antibodies including SNS-101, SNS-102, SNS-103, and SNS-201, targeting various immunosuppressive markers within the tumor microenvironment.

What is SNS-101?

SNS-101 is a conditionally active antibody designed to block the VISTA checkpoint within the acidic tumor microenvironment, currently in Phase 1/2 clinical trials.

What are the recent achievements of the company?

Recent achievements include promising initial data from the Phase 1/2 trial of SNS-101, showing favorable safety and clinical activity in patients with advanced solid tumors.

Where is Sensei Biotherapeutics headquartered?

Sensei Biotherapeutics is headquartered in Gaithersburg, MD.

What is the TMAb™ platform?

The TMAb™ (Tumor Microenvironment Activated biologics) platform is Sensei's proprietary technology for developing conditionally active therapeutics targeting the tumor microenvironment.

What financial status does Sensei Biotherapeutics have?

Sensei maintains a strong balance sheet, with cash reserves projected to fund operations into the second half of 2025, and has reduced R&D and G&A expenses due to strategic restructuring.

Who are Sensei's key collaborators?

Sensei has established key academic collaborations, including with Brown University, to support its research and development efforts.

What are the anticipated milestones for SNS-101?

Anticipated milestones include initial pharmacokinetic and safety data in Q1 2024, with topline monotherapy data expected later in 2024.

Where can I find more information about Sensei Biotherapeutics?

For more information, visit Sensei’s website at www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Sensei Biotherapeutics, Inc.

Nasdaq:SNSE

SNSE Rankings

SNSE Stock Data

11.06M
16.54M
34.39%
8.81%
0.77%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ROCKVILLE